


NOV 20 2003

RCE/1600
H

NOV 19 2003



PTO/SB/03 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

**Request
For
Continued Examination (RCE)
Transmittal**

Address to:
Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

| | |
|-------------------------------|------------------|
| <i>Application Number</i> | 09/835,501 |
| <i>Filing Date</i> | April 16, 2001 |
| <i>First Named Inventor</i> | Tyler B. Parr |
| <i>Art Unit</i> | 1615 |
| <i>Examiner Name</i> | Robert M. Joynes |
| <i>Attorney Docket Number</i> | |

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.
Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1895, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. **Submission required under 37 CFR 1.114** Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).

- a. Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.

- i. Consider the arguments in the Appeal Brief or Rely Brief previously filed on _____
ii. Other _____

- b. Enclosed

- i. Amendment/Reply
ii. Affidavit(s)/ Declaration(s)

- iii. Information Disclosure Statement (IDS)
iv. Other _____

2. **Miscellaneous**

- a. period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)
b. Other _____

3. **Fees** The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.

- The Director is hereby authorized to charge the following fees, or credit any overpayments, to
a. Deposit Account No. _____

- i. RCE fee required under 37 CFR 1.17(e)
ii. Extension of time fee (37 CFR 1.135 and 1.17)
iii. Other _____

11/21/2003 JADD01 00000062 09835501
01 FC:2801 385.00 OP

- b. Check in the amount of \$ 385.00 enclosed (*Small entity*)
c. Payment by credit card (Form PTO-2038 enclosed)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

| | | | |
|--------------------------------|---------------------------------------|---|-------------|
| Name (Print/Type) Signature | Tyler B. Parr <i>Tyler B. Parr</i> | Registration No. (Attorney/Agent) Date | 19 Nov 2003 |
|--------------------------------|---------------------------------------|---|-------------|

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

| | | | |
|--------------------------------|---------------------------------------|------|-------------|
| Name (Print/Type) Signature | Tyler B. Parr <i>Tyler B. Parr</i> | Date | 19 Nov 2003 |
|--------------------------------|---------------------------------------|------|-------------|

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Applicant : Tyler B. Parr
Appl. No. : 09/835,501
Filed : April 16, 2001
Title : Chemical Synergy to Elevate Growth
Hormone Release in Vertebrates

Grp./A.U. : 1615 (?)
Examiner : Robert M. Joynes

Docket No. : 7590 (?)

RECEIVED
NOV 26 2003
TECH CENTER 2900

Sir:

In response to the Office Action of 10/22/03 (Oct 22, 2003), please amend the identified application as follows:

In the claims:

Please amend claims 1 and 6 as follows:

1. (Currently amended) A method of augmenting endogenous vertebrate growth hormone release by a chemical synergy between oral intake of a component 1 the compound acetyl-L-carnitine and a component 2 the compound L-ornithine.
2. (Previously amended) The method in Claim 1 wherein component 1 may also be a substance selected from a group consisting of acetyl-L-carnitine, any acylated ester of L-carnitine having an acyl chain of three to six carbon length, pharmacological acceptable salts thereof, mixtures thereof, and a pharmacological appropriate dose over the range of 10 milligrams to 20 grams.
3. (Previously amended) The method in Claim 1 wherein component 2 may